Products for Research Use Only
RegisterLogin

T025

CAT: 0804-HY-112296-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112296-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM) . T025 has an anti-tumor efficiency, mainly for MYC-driven disease research[1].
CAS Number
2407433-00-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; CDK; DYRK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/T025.html
Purity
99.64
Solubility
DMSO : 8.25 mg/mL (ultrasonic)
Smiles
CNC1=NC(NCC2=NC=CC=N2)=C(C(C3=CC=C(N=CC=C4)C4=C3)=CN5)C5=N1
Molecular Formula
C21H18N8
Molecular Weight
382.42
Precautions
H302, H315, H319
References & Citations
[1]Iwai K, et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med. 2018 Jun;10 (6) :e8289.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CLK; DYRK1; DYRK2

Related Products

CatalogName
HY-117233-01UU-T02

Alternative Products

CatalogName
BA2818-10T025

Popular Products